Agios Pharmaceuticals Inc. (AGIO), pioneering therapies for rare diseases, has a couple of clinical trial catalysts to watch this year.The company's flagship drug is Mitapivat, approved for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency in the U.S., EU and Great Britain, under the brand name Pyrukynd. Pyrukynd generated sales of $8.2 million in the first quarter of 202...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.